new PCSK9 inhibitor pelacarsen withdrawn after trial
Pelacarsen, the most intensive Lipoprotein (a) antagonist (hereinafter Lp(a)) was just found to be clinically ineffective in the Lp(a) HORIZON Phase III study from Novartis because it "did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular heath, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo": https://www.globenewswire.com/news-release/2026/09/04/3356808/0/en/novartis-announces-lp-a-horizon-phase-iii-topline-results-for-pelacarsen-in-patients-with-elevated-lp-a-and-established-cardiovascular-disease-cvd.html for the New York Times comments: https://www.nytimes.com/2026/09/04/science/heart-drug-fails-novartis-pelacarsen.html?unlocked_article_code=1._FA.allS.qNH-hHuEvKoV&smid=url-share Details : -- there are not many details in the Novartis statement, though the plan is to present the data at the annual meeting of the American ...